Pluristem's PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant Patients

By: via Benzinga
Pluristem Therapeutics Inc(NASDAQ: PSTI)announced final resultsfrom its hematology Phase 1 study of intramuscular ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.